Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions

PULSE BIOSCIENCES, INC.

GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).
Cash $106.3M at June 30 (down from $119.3M at March 31); operating cash burn $12.8M in Q2.
FDA IDE applications submitted for nsPFA cardiac surgical clamp and 360° catheter AF pivotal studies.
Over 140 benign thyroid nodule patients treated; expanded pilot program; post-market study enrollment planned Q3 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.